Antibacterial Effect Of Natural Oils – An Opportunity To Solve The Problem Of Antibiotic Resistance On The Example Of Pseudomonas Spp.
, , and | Oct 15, 2019
About this article
Article Category: article
Published Online: Oct 15, 2019
Page range: 177 - 190
Received: Nov 01, 2018
Accepted: Apr 01, 2019
DOI: https://doi.org/10.21307/PM-2019.58.2.177
© 2019 Katarzyna Leja et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
![Phenotypic expression of antibiotic resistance. Based on Doughari et al. [20].](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/6470922671e4585e08aa02e1/j_PM-2019.58.2.177_fig_004.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20240723T142225Z&X-Amz-SignedHeaders=host&X-Amz-Expires=18000&X-Amz-Credential=AKIA6AP2G7AKP25APDM2%2F20240723%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Signature=4e2f980f79f29f6f930c43da38554b533c7031bdd1ba4bc225d7561c3619d472)
Fig. 5.
Minimum inhibitory concentrations of EOs against Pseudomonas strains
| Origin of EO | Strain | Reference | |
|---|---|---|---|
| MIC | |||
| > 1000 μg/ml | N/A | 85 | |
| N/A | > 0.8% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| > 0.8% v/v | 36–37; 84 | ||
| 36–37 | |||
| > 2.0% v/v | N/A | 84 | |
| N/A | > 0.8% v/v | 36–37 | |
| 0.05% v/v | |||
| 0.1% v/v | |||
| > 2.0% v/v | N/A | 84 | |
| > 0.8% v/v | 36–37; 84 | ||
| N/A | 36–37; 84 | ||
| > 2.0% v/v | 36–37; 84 | ||
| N/A | 84 | ||
| N/A | > 0.8% v/v | 37 | |
| > 2.0% v/v | N/A | 84 | |
| N/A | > 0.8% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| 0.8% v/v | 36–37 | ||
| N/A | 0.025% v/v | ||
| > 0.8% v/v | |||
| > 2.0% v/v | N/A | 84 | |
| > 0.8% v/v | 36–37; 84 | ||
| N/A | 36–37 | ||
| > 2.0% v/v | 0.8% v/v | ||
| 0.2% v/v | |||
| 0.4% v/v | |||
| N/A | 84 | ||
| N/A | > 0.8% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| N/A | 0.1% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| N/A | > 0.8% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| N/A | > 0.8% v/v | 36–37 | |
| > 2.0% v/v | N/A | 54 | |
| 10.0 μg/ml | 54 | ||
| > 2.0% v/v | 0.8% v/v | 36–37; 84 | |
| > 0.8% v/v | |||
| 3.0 μg/ml | N/A | 54 | |
| > 2.0% v/v | 84 | ||
| N/A | > 0.8% v/v | 36–37 | |
| > 2.0% v/v | 36–37; 84 | ||
| 0.4% v/v | |||
| N/A | 84 | ||
| N/A | 0.1% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| > 0.8% v/v | 36–37; 84 | ||
| N/A | 84 | ||
| > 1000 μg/ml | 85 | ||
| > 2.0% v/v | 84 | ||
| > 1000 μg/ml | 85 | ||
| > 2.0% v/v | > 0.8% v/v | 36–37; 84 | |
| N/A | 0.8% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| N/A | 0.05% v/v | 36–37 | |
| > 2.0% v/v | N/A | 84 | |
| 4.0% v/v | 87 | ||
| > 2.0% v/v | 0.05% v/v | 36–37; 84 | |
| N/A | 84 | ||
| > 0.8% v/v | 36–37; 84 | ||